AstraZeneca shares soar as Enhertu found to reduce breast cancer risks
Category: #healthcare  By Akshay Kedari  Date: 2021-09-22
  • share
  • Twitter
  • Facebook
  • LinkedIn

AstraZeneca shares soar as Enhertu found to reduce breast cancer risks

Shares of AstraZeneca plc have witnessed a substantial hike after it revealed positive results from Enhertu trials, a breast cancer drug candidate which is being developed by the British drugmaker.

If sources are to be believed, Enhurtu reduced the chances of death and slowed down the rate of cancer progression and tumor formation by 72% as compared to trastuzumab emtansine (Kadcyla), the drug which is currently being used for treating HER2-positive unresectable or metastatic breast cancer.

The Phase 3 trial called DESTINY-Breast03 involved a comparative analysis of Enhertu and Kadcyla in over 500 women whose tumors had high levels of the HER2 protein. The study results reported that 75.8% of patients treated with Enhertu showed no disease progression after one year into treatment as compared to 34.1% in those who were treated with trastuzumab emtansine.

Javier Cortes, Head of International Breast Cancer Center was quoted saying that these trial results support the potential of Enhertu to become the new benchmark for treating those who have previously been diagnosed with HER2-positive metastatic breast cancer.

Executive Vice President of Oncology R&D at AstraZeneca’s Dr. Susan Galbraith reportedly said that the new drug tripled progression-free survival among breast cancer patients, having a disease control rate of more than 95%.

As per early survival data, approximately all patients treated with Enhertu were found to be alive a year after the drug was administered, which is quite a positive indication for the treatment’s potential. Even the safety profile of the most commonly occurring events from the treatment was found to be consistent with Astra Zeneca’s previous clinical trials.

It is worth noting here that the most common grade 3 or higher treatment event recorded included a lower white blood cell count which occurred in approximately 20% of the patients. 

AstraZeneca shares, when last checked, rose by 4.6% to USD 58.10. On July 12, the company’s stock had touched a 52 week high at USD 61.

Source Credits—

https://www.thestreet.com/investing/astrazeneca-stock-rises-breast-cancer-drug-progress

 

About Author

Akshay Kedari    

Akshay Kedari

Akshay holds a Bachelor’s degree in computer engineering. Despite having a penchant for software development and the like, Akshay took to writing as a career owing to his passion for the field. Presently, Akshay writes articles for itresearchbrief.com and a few oth...

Read More>>

More News By Akshay Kedari

Power Global to invest USD 25 Mn to build battery-making unit in India
Power Global to invest USD 25 Mn to build battery-making unit in India
By Akshay Kedari

United States-based startup Power Global is reportedly planning to invest USD 25 million to develop ...

Robo-advisor startup Fount raises USD 33.4 million in Series C funding
Robo-advisor startup Fount raises USD 33.4 million in Series C funding
By Akshay Kedari

South Korea-based AI investment solution company Fount has reportedly raised USD 33.4 million in a S...

Mercedes-Benz India expects to cross 10,000 vehicle sales by year-end
Mercedes-Benz India expects to cross 10,000 vehicle sales by year-end
By Akshay Kedari

Demand for cars and after sales services has increased since the second half of June 2021. The co...